{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:23:03Z","timestamp":1759191783866,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jhep.2020.11.031","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T10:21:10Z","timestamp":1607509270000},"page":"755-756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reply to: \u201cBoth tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis\u201d"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-3129","authenticated-orcid":false,"given":"Ansgar W.","family":"Lohse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5163-6979","authenticated-orcid":false,"given":"Marcial","family":"Sebode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Vesterhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jhep.2020.11.031_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","article-title":"A\u00a0systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment","volume":"30","author":"De Lemos-Bonotto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.11.031_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/MPG.0000000000001530","article-title":"Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis","volume":"65","author":"Zizzo","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"33","key":"10.1016\/j.jhep.2020.11.031_bib3","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Terziroli Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2020.11.031_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/MEG.0000000000001580","article-title":"Profiling\u00a0the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience","volume":"32","author":"Pape","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2020.11.031_bib5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820338186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:23Z","timestamp":1759174883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820338186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0168827820338186"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: \u201cBoth tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.07.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.09.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}